Websites
Xinxue Liu
Associate professor of medical statistics and epidemiology
I completed a Preventive Medicine Degree at Peking University. After that, I was trained in Epidemiology and Biostatistics at Peking University and University of Cambridge and obtained my PhD and MPhil degrees.
I joined the Oxford Vaccine Group Department of Paediatrics in 2017 after receiving more than 4 years of training as a Research Fellow (Clinical Trial Statistician) at the Imperial Clinical Trial Unit.
My experiences in trials cover a broad range of therapeutic areas, including cancer, surgery, nutrition and vaccination and ranging from early phase to late phase. My research interest is mainly in developing efficient trial designs and practical implementation of such designs in clinical trials, for example, model based adaptive designs in early phase dose-finding trials evaluating safety and efficacy. I am also interested in applying biomarkers in late phase trial design and benefit and risk assessment.
Recent publications
-
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Journal article
Kelly S. et al, (2023), Trials, 24
-
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2023), J Infect, 87, 18 - 26
-
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect
-
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
-
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.
Journal article
McCann N. et al, (2023), BMJ Open, 13, e068966 - e068966